in recent phase II DAA studies, IL28B status still mattered in predicting outcome in genotype 1 patients being treated with
interferon-free regimens. .....subtype
1b patients, responsiveness was excellent across the board, regardless IL28B status. By contrast, those subtype 1a patients with non-CC IL28B genotypes did poorly compared with those with the CC genotype who performed as well as the 1b subjects.